FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The results of the study showed that men with Charlson scores of 2+ (age <75) and 3+ (age ≥75) comprised of the lowest quartile of health. Among those <65, 65-69, 70-74, 75-79, and ≥80 years, observed survival vs NCCN-predicted life expectancy in years was similar: 10.4 vs. 16 11.1, 10.0 vs. 7.8, 6.2 vs. 6.4, 4.4 vs. 4.9, and 3.7 vs. 3.3, respectively. Although on average survival of those in lowest quartile of health was similar to NCCN-predicted survival, there was significant heterogeneity in survival among men differing Charlson scores. This demonstrates that NCCN guidelines misclassified 10-year life expectancy in 24% and 56% of men aged <65 and 65-69, and 5-year life expectancy in 18% of men age 70-74.
The heterogeneity in survival among those with different Charlson scores led to over- and underestimation of survival by the NCCN Method. In conclusion, the findings in this study argue that a more accurate determination of life expectancy assessment needed when deciding treatment for men with prostate cancer, one that integrate both Charlson comorbidities with the NCCN method.
Authors: Timothy J. Daskivich, MD, MSHPM, Laudren, MD, Douglas Skarecky, AB, Thomas Ahlering, MD, Stephen Freedland, MD
Affiliations: 1Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 2Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, Los Angeles, CA 3Department of Urology, University of California, Irvine, Irvine, California 4Long Beach Veterans Affairs Medical Center, Long Beach, California 5Durham Veterans Affairs Medical Center, Durham, North Carolina
Read the Abstract
Kent M, Vickers AJ. A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer. J Urol. 2015;193(6):1938-1942.
Sammon JD, Abdollah F, D'Amico A, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol. 2015;68(5):756-765.
Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19-30.
Daskivich TJ, Lai J, Dick AW, et al. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. Cancer. 2014;120(16):2432-2439
Heidenreich A, Bellmunt J, Bolla M, et al. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp. 2011;35(9):501-514.